Pharmacological Efficacy of Intravenous Magnesium in Attenuating Remifentanil-Induced Postoperative Hyperalgesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Pharmaceuticals · 01.04.2025 · 18 (4) · 518
DOI: 10.3390/ph18040518 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 01.04.2025. Verfasst von En-Bo Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, China Medical University Hospital, China Medical University, Taichung City 404, Taiwan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University Hospital.
Abstract (Originalsprache)
Background/Objectives: Remifentanil-based anesthesia is linked to opioid-induced hyperalgesia (OIH), increasing postoperative pain and analgesic requirements. Magnesium, an N-methyl-D-aspartate (NMDA) receptor antagonist, might alleviate OIH. We aimed to assess whether intravenous magnesium reduces postoperative pain, analgesic requirements, and hyperalgesia in adults receiving remifentanil-based anesthesia.
Methods
We searched PubMed, Embase, the Cochrane Library, and Web of Science (1 December 2024) for randomized controlled trials (RCTs) comparing intravenous magnesium vs. placebo. Risk of bias was evaluated with the Cochrane RoB 2 tool, and random-effects meta-analyses were conducted. GRADE was used to assess evidence quality. Primary outcomes were postoperative analgesic requirements and pain scores; secondary outcomes included intraoperative remifentanil consumption, shivering, postoperative nausea/vomiting (PONV), extubation time, hypotension, and bradycardia. PROSPERO registration: CRD42024609911.
Results
Twenty-two RCTs (n = 1362) met eligibility. Magnesium significantly decreased 24 h analgesic requirements (standardized mean difference [SMD] −1.51; 95% confidence interval [CI] −2.15 to −0.87; p < 0.0001) and pain scores (SMD −0.61; 95% CI −0.90 to −0.32; p < 0.0001), with benefits persisting up to 48 h. It also reduced intraoperative remifentanil use (SMD −0.52), shivering (odds ratio [OR] 0.25), and PONV (OR 0.66), without prolonging extubation or increasing hypotension/bradycardia risk. High heterogeneity, potential publication bias, and moderate-to-very-low evidence certainty warrant caution.
Conclusions
Intravenous magnesium appears beneficial in remifentanil-based anesthesia, but further large-scale, methodologically robust trials are needed to confirm optimal and clarify safety profiles across diverse surgical populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology, China Medical University Hospital, China Medical University, Taichung City 404, Taiwan.
- Division of Colorectal Surgery, Department of Surgery, Kaohsiung Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Kaohsiung City 833, Taiwan.
- Department of Anesthesiology, School of Medicine, China Medical University, Taichung City 404, Taiwan.
ORCID-Profile: En-Bo Wu, Wei-Ti Hsu, Wei-Chin Yuan
Förderung
- China Medical University Hospital
Zitieren
APA
Wu, E. B., Wu, K. L., Hsu, W. T., Yuan, W. C., & Chen, K. B. (2025). Pharmacological Efficacy of Intravenous Magnesium in Attenuating Remifentanil-Induced Postoperative Hyperalgesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmaceuticals, 18(4), 518. https://doi.org/10.3390/ph18040518
Vancouver
Wu EB, Wu KL, Hsu WT, Yuan WC, Chen KB. Pharmacological Efficacy of Intravenous Magnesium in Attenuating Remifentanil-Induced Postoperative Hyperalgesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmaceuticals. 2025;18(4):518. doi:10.3390/ph18040518
BibTeX
@article{Wu2025,
author = {Wu, En-Bo and Wu, Kuen-Lin and Hsu, Wei-Ti and Yuan, Wei-Chin and Chen, Kuen-Bao},
title = {Pharmacological Efficacy of Intravenous Magnesium in Attenuating Remifentanil-Induced Postoperative Hyperalgesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {4},
pages = {518},
doi = {10.3390/ph18040518}
}
EUVIMED